abstract:
Tumor BRCA1 Reversion Mutation Arising During Neoadjuvant
Platinum-Based Chemotherapy in Triple-Negative Breast Cancer Is
Associated with Therapy Resistance
BACKGROUND:
In
germline BRCA1 or BRCA2 (BRCA1/2) mutation carriers,
restoration of
tumor BRCA1/2 function by a secondary mutation is recognized as a
mechanism of resistance to platinum and PARP inhibitors, primarily in
ovarian cancer. We evaluated this mechanism of resistance in newly
diagnosed
BRCA1/2-mutant breast cancer patients with poor response to
neoadjuvant platinum-based therapy.
METHODS:
PrECOG
0105 was a phase II neoadjuvant study of gemcitabine, carboplatin and
iniparib in patients with stage I-IIIA triple-negative or BRCA1/2
mutation-associated breast cancer (n=80). All patients underwent
comprehensive BRCA1/2 genotyping. For mutation carriers with moderate or
extensive residual disease after neoadjuvant therapy, BRCA1/2 status
was re-sequenced in the residual surgical breast tumor tissue.
RESULTS:
Nineteen
patients had a deleterious germline BRCA1/2 mutation and 4 had moderate
residual disease at surgery.
BRCA1/2 sequencing of residual tissue was
performed on three patients. These patients had BRCA1 1479delAG,
3374insGA and W1712X mutations, respectively, with loss of
heterozygosity at these loci in the pre-treatment tumors.
In the first
case, a new BRCA1 mutation was detected in the residual disease. This
resulted in a 14 amino acid deletion and restoration of the BRCA1
reading frame. A local relapse biopsy four months later revealed the
identical reversion mutation, and the patient subsequently died of
metastatic breast cancer.
CONCLUSIONS:
We
report a BRCA1 reversion mutation in a newly diagnosed triple-negative
breast cancer patient that developed over 18 weeks of platinum-based
neoadjuvant therapy. This was associated with poor therapy response,
early relapse and death.
0 comments :
Post a Comment
Your comments?
Note: Only a member of this blog may post a comment.